Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
ruxolitinib XR
/
Incyte
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||
||||||||
ruxolitinib XR
/
Incyte
,
Jakafi
(ruxolitinib) /
Incyte
New P1 trial:
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
(clinicaltrials.gov) - Mar 15, 2024
P1
, N=12, Recruiting,
Sponsor: Incyte Corporation
||||
||||||
ruxolitinib XR
/
Incyte
,
Jakafi
(ruxolitinib) /
Novartis, Incyte
Clinical, FDA event:
The #FDA has issued a complete response letter for #ruxolitinib extended-release tablets for once-daily use for the treatment of certain types of #myelofibrosis, polycythemia vera, and #GVHD. #mpnsm | @AaronGerds @ClevelandClinic https://t.co/m7YHjP86sY
(Twitter) - Mar 23, 2023